

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please send an e-mail to: ocod@fda.hhs.gov and include 508 Accommodation and the title of the document in the subject line of your e-mail.

BLOOD GROUPING REAGENT

Anti-Fy^a

ALBAclone[®]

(Monoclonal IgG)

For Tube Techniques

REF Z152U

- FOR *IN VITRO* DIAGNOSTIC USE
- Meets FDA potency requirements
- Discard if turbid
- Preservative:

0.09 - 0.1% (w/v) sodium azide and
<0.02% (w/v) sodium arsenite

CAUTIONS: THE ABSENCE OF ALL VIRUSES HAS NOT BEEN DETERMINED. THIS PRODUCT HAS COMPONENTS (DROPPER BULBS) CONTAINING DRY NATURAL RUBBER.

INTERPRETATION OF LABELING SYMBOLS



Batch code



Use by (YYYY-MM-DD)



Product code



Storage temperature limitation (2-8 °C)



In vitro diagnostic medical device



Consult instructions for use



Manufacturer

INTENDED USE

This Anti-Fy^a reagent is for the *in vitro* detection and identification of the human Fy^a blood group antigen by Indirect Antiglobulin Test.

SUMMARY AND EXPLANATION

Anti-Fy^a and anti-Fy^b were described in 1950 and 1951 respectively. FY^{*A} and FY^{*B} are a pair of alleles on the long arm of chromosome 1, giving rise to three commonly

encountered phenotypes: Fy(a+b-), Fy(a+b+) and Fy(a-b+). Fy^a and Fy^b antigens are destroyed when the red blood cells are treated with appropriate concentrations of the proteolytic enzymes ficin, papain, and α-chymotrypsin.

PRINCIPLE OF THE TEST

When used by the recommended technique, this reagent will cause the agglutination (clumping) of red blood cells carrying the Fy^a antigen. Lack of agglutination demonstrates the absence of the Fy^a antigen.

REAGENT DESCRIPTION

The main component of this reagent is derived from the *in vitro* culture of the IgG secreting human/mouse heterohybridoma:

Product Name	Product Code	Cell Line
Anti-Fy ^a	Z152U	DG-FYA-02

The formulation also contains bovine material, potentiator, 0.09 - 0.1% (w/v) sodium azide and <0.02% (w/v) sodium arsenite

NOTE: The volume delivered by the reagent bottle dropper is approximately 40 µL. Care should be taken to ensure that appropriate serum to cell ratios are maintained in all test systems.

WARNINGS AND PRECAUTIONS

For *in vitro* diagnostic use only

Products should be used by qualified personnel

Do not use beyond the expiration date

Do not use if turbid

Do not dilute

The format of the expiration date is expressed as YYYY-MM-DD (Year-Month-Day)

This reagent contains 0.09 - 0.1% (w/v) sodium azide. Sodium azide may be toxic if ingested and may react with lead and copper plumbing to form explosive compounds. If discarded into a sink, flush with a large volume of water to prevent azide build-up.

This reagent contains material of animal origin (murine and bovine), therefore care must be taken during use and disposal as there is a potential infection risk.

CAUTION: ALL BLOOD PRODUCTS SHOULD BE TREATED AS POTENTIALLY INFECTIOUS. SOURCE MATERIAL FROM WHICH THIS PRODUCT WAS DERIVED WAS FOUND NEGATIVE WHEN TESTED IN ACCORDANCE WITH CURRENT FDA REQUIRED TESTS. NO KNOWN TEST METHODS CAN OFFER ASSURANCE THAT PRODUCTS DERIVED FROM HUMAN BLOOD WILL NOT TRANSMIT INFECTIOUS AGENTS.

The bovine material used in the manufacture of this reagent was collected in a USDA approved facility or obtained from a geographical region classified as negligible risk for BSE

Monoclonal antibodies exhibit a high degree of potency, avidity and specificity. When using such antibodies, great care should be taken to avoid cross contamination.

This product has components (dropper bulbs) containing dry natural rubber.

STORAGE

The reagent should be stored at 2-8 °C.

SPECIMEN COLLECTION AND PREPARATION

Specimens should be collected by a standard collection technique. The specimen should be tested as soon as possible after collection. If testing is delayed, the specimen should be stored at refrigerated temperatures.

Clotted samples, or those collected in EDTA, should be tested within fourteen days from collection. Donor blood collected in ACD, CPD, CPDA -1, CP2D, CP2D with AS-3, CPD with AS-1, and CPD with AS-5 may be tested until the expiration date of the donation.

Special care should be taken if hemolyzed samples must be tested. Grossly icteric or contaminated blood specimens should not be used.

MATERIALS

Material provided

- ALBAclone[®] Anti-Fy^a

Materials required but not provided

- Isotonic saline
- Reagent red blood cells suitable for the control of Anti-Fy^a
- Polyspecific Anti-Human Globulin/Monospecific Anti-Human IgG
- IgG sensitized red blood cells
- 10 x 75 mm or 12 x 75 mm glass test tubes
- Pipettes
- Optical aid (optional)
- Centrifuge
- Timer
- Heating block/waterbath

PROCEDURE

NOTE: This reagent has been standardized for use by the technique described below and therefore its suitability for use by other techniques cannot be guaranteed. When a test is required to be incubated for a specific time period, a timer should be used.

When using supplemental testing equipment (i.e. centrifuge), follow the procedures that are contained in the operator's manual provided by the device manufacturer.

Indirect Antihuman Globulin Test

- Prepare a 2-4% suspension of red blood cells in isotonic saline solution (Reagent Red Blood Cells may be used directly from the vial or according to the manufacturer's instructions.)
 - Add 1 drop of blood grouping reagent to a glass test tube.
 - Add 1 drop of red blood cell suspension. Steps 2 and 3 may be performed in either order.
 - Mix the contents of the test tube and incubate at 37 °C ± 1 °C for 15-30 minutes.
Wash the test 3-4 times with a large excess of isotonic saline (e.g. 4 mL of saline per 10 (or 12) x 75 mm glass test tube).
- NOTE: (i) allow adequate spin time to sediment the red blood cells.

- (ii) make sure that the residual saline is removed at the end of each wash.
- Add 2 drops of anti-human globulin reagent to each test tube.
 - Mix the contents of the test tube and centrifuge.
NOTE: Suggested centrifugation: 900-1000 g (approx. 3400 rpm) for 10 seconds or a time and speed appropriate for the centrifuge used that produces the strongest reaction of antibody with antigen-positive red blood cells, yet allows easy re-suspension of antigen-negative red blood cells.
 - After centrifugation, gently shake the tube to dislodge the cell button from the bottom and immediately observe macroscopically for agglutination. Negative reactions may be examined with an optical aid.
 - Record results.
 - The validity of all negative tests should be confirmed using IgG sensitized reagent red cells.
 - Add 1 drop of IgG sensitized reagent red blood cells to each negative antiglobulin test.
 - Mix the contents of the test tube well and centrifuge.
NOTE: Suggested centrifugation: 900-1000g (approx. 3400 rpm) for 10 seconds or a time and speed appropriate for the centrifuge used that produces the strongest reaction of positive tests yet allows easy re-suspension of negative tests.
 - After centrifugation, gently shake the tube to dislodge the cell button from the bottom and immediately observe macroscopically for agglutination.
 - Any test which does not show a positive reaction should be considered invalid and repeated.

Refer to Performance Limitations section for additional guidance on the use of this product

STABILITY OF REACTION

Test results should be read, interpreted and recorded immediately after centrifugation. Delays may cause dissociation of antigen-antibody complexes resulting in weak positive or false negative reactions.

INTERPRETATION OF RESULTS

Agglutination = positive test result
No agglutination = negative test result

QUALITY CONTROL

Quality control of reagents is essential and should be performed on each day of use and in accordance with local, state and federal regulations.

Fy(a+b+) red blood cells should be used as a positive control
Fy(a-b+) red blood cells should be used as a negative control

Other red blood cell types may be suitable but should be selected with care.

All negative antiglobulin tests should be controlled using IgG sensitized reagent red blood cells. A positive result indicates the presence of active anti-IgG. A negative result should be considered invalid and repeated if necessary.

PERFORMANCE LIMITATIONS

NOTE: Any saline present after the completion of the wash phase may dilute the Anti-Human Globulin reagent beyond its optimal working concentration. Therefore it is important to ensure that the maximum amount of wash solution is removed after each centrifugation step.

Red blood cells that are direct antiglobulin test positive should not be tested using the Indirect Antihuman Globulin Test.

Heating blocks and waterbaths promote better heat transfer and are recommended for 37 °C tests, particularly where the incubation period is 30 minutes or less.

The expression of certain red blood cell antigens may diminish in strength during storage, particularly in EDTA and clotted samples. Better results will be obtained with fresh samples.

Gently re-suspend tube tests before reading. Excessive agitation may disrupt weak agglutination and produce false negative results.

Excessive centrifugation can lead to difficulty in re-suspending the cell button, while inadequate centrifugation may result in agglutinates that are easily dispersed.

False positive or false negative results can occur due to contamination of test materials, improper reaction temperature, improper storage of materials, omission of test reagents and certain disease states.

Suppressed or weak expression of blood group antigens may give rise to false negative reactions

SPECIFIC PERFORMANCE CHARACTERISTICS

Prior to release, each lot of ALBAclone® Anti-Fy^a is tested using FDA recommended methods against a panel of antigen-positive and antigen-negative red blood cells to ensure suitable reactivity.

In performance evaluation studies (data on file at Alba Bioscience Limited), blood group samples were tested with ALBAclone® Anti-Fy^a as follows:

Reagent	No. Samples Tested	Concordance*
ALBAclone® Anti-Fy ^a	1106	99.9%

* Concordance indicated agreement between the ALBAclone® Anti-Fy^a and comparator reagents only and does not indicate which reagent gave the correct results.

Repeatability and reproducibility of the trial reagent was confirmed by means of Lot to Lot and Precision studies.

Comparator Study Results

During comparator studies (data on file at Alba Bioscience Limited), blood samples were tested with ALBAclone® Anti-Fy^a (Monoclonal) (IgG) as follows:

Anti-Fy ^a		Comparator Reagent			One-sided 95% Exact lower confidence limit
		Positive	Negative	Total	
Trial Reagent	Positive	662	1	663	
	Negative	0	443	443	
	Total	662	444	1106	
Positive Percent Agreement*				100	99.55%
Negative Percent Agreement*				99.77	98.94%

* Indicates agreement between the ALBAclone® Anti-Fy^a and comparator reagents only and does not indicate which reagent gave the correct result(s).

In performance evaluation studies, 1106 samples were tested with ALBAclone® Anti-Fy^a (Monoclonal) (IgG). The positive percent agreement at the one-sided 95% exact lower confidence limit was 99.55% for agglutination tests based on a comparison of interpreted results. The negative agreement at the one-sided 95% exact lower confidence limit was 98.94% for agglutination tests based on a comparison of interpreted results. The following factor may have had an impact on the outcome of the testing and the discrepancies observed:

- Test site investigation suggested that the discrepancy may have been due to transcription error in the original test.

Results were evaluated against comparable FDA approved products using the appropriate methods for the comparators.

Precision Study Results

As part of the performance evaluation, precision and lot to lot studies were performed using multiple operators, days and runs to confirm repeatability and reproducibility of test results in the same run, day and with the same operator and between runs, days and operators. The study took account of variables such as days of the week, times of day and supplementary reagents used in the testing.

All antigen positive test outcomes generated unequivocal positive reactions and antigen negative test outcomes generated unequivocal negative reactions.

BIBLIOGRAPHY

- Roback JD, Grossman BJ, Harris T, *et al*: AABB Technical Manual, 18th ed. AABB, 2014
- AABB Standards Program Committee: Standards for Blood Banks and Transfusion Services, 29th ed. AABB, 2014
- Reid ME, Lomas-Francis C, Olsson ML: The Blood Group Antigen FactsBook, ed 3. Academic Press, 2012

DATE OF ISSUE

YYYY-MM-DD

US Distributor

Quotient
301 South State Street
S-204
Newtown
PA 18940
USA

Customer Service Tel: 1-888-284-1901
Product Technical Support Tel: 1-888-228-1990
Customer Service Fax: 1-888-694-5208
E-Mail: customer.serviceUS@quotientbd.com
Web: www.quotientbd.com/us



Alba Bioscience Limited
Ellen's Glen Road
Edinburgh
Scotland, UK
EH17 7QT

US License 1807